Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Nov;20(5):447–451. doi: 10.1111/j.1365-2125.1985.tb05095.x

The peripheral vascular effects of diltiazem--dose-response characteristics.

M B Finch, G D Johnston
PMCID: PMC1400713  PMID: 4074614

Abstract

The acute effects of increasing doses of diltiazem on peripheral blood flow were observed in six subjects. Each subject received, in random order, a single oral dose of placebo or diltiazem 60, 120 or 180 mg. Supine heart rate, blood pressure, skin temperature, digital systolic pressure, forearm and digital blood flow were recorded before and at 1, 2, 3, 4 and 6 h post-dosing. Plasma diltiazem concentrations were measured at each time interval and at 12 and 24 h after the 120 mg dose. At doses of 120 and 180 mg, diltiazem significantly increased digital blood flow at 1, 2, 3, 4 and 6 h post-dosing and forearm blood flow at 2 and 3 h following 180 mg and 3 h following 120 mg. No correlation was observed between plasma diltiazem concentration and changes in peripheral blood flow.

Full text

PDF
447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Bondesson U., Sylvén C., Aström H. Plasma concentration--response relationship of verapamil in the treatment of angina pectoris. J Cardiovasc Pharmacol. 1982 Jul-Aug;4(4):609–614. doi: 10.1097/00005344-198207000-00012. [DOI] [PubMed] [Google Scholar]
  2. Andreasen F., Boye E., Christoffersen E., Dalsgaard P., Henneberg E., Kallenbach A., Ladefoged S., Lillquist K., Mikkelsen E., Norder0 E. Assessment of verapamil in the treatment of angina pectoris. Eur J Cardiol. 1975 Apr;2(4):443–452. [PubMed] [Google Scholar]
  3. Antman E., Muller J., Goldberg S., MacAlpin R., Rubenfire M., Tabatznik B., Liang C. S., Heupler F., Achuff S., Reichek N. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980 Jun 5;302(23):1269–1273. doi: 10.1056/NEJM198006053022301. [DOI] [PubMed] [Google Scholar]
  4. Hermann P., Rodger S. D., Remones G., Thenot J. P., London D. R., Morselli P. L. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol. 1983;24(3):349–352. doi: 10.1007/BF00610053. [DOI] [PubMed] [Google Scholar]
  5. Hossack K. F., Bruce R. A. Improved exercise performance in persons with stable angina pectoris receiving diltiazem. Am J Cardiol. 1981 Jan;47(1):95–101. doi: 10.1016/0002-9149(81)90296-4. [DOI] [PubMed] [Google Scholar]
  6. Kinney E. L., Moskowitz R. M., Zelis R. The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers. J Clin Pharmacol. 1981 Aug-Sep;21(8-9):337–342. doi: 10.1002/j.1552-4604.1981.tb01778.x. [DOI] [PubMed] [Google Scholar]
  7. Kinney E. L., Nicholas G. G., Gallo J., Pontoriero C., Zelis R. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol. 1982 Jan;22(1):74–76. doi: 10.1002/j.1552-4604.1982.tb05712.x. [DOI] [PubMed] [Google Scholar]
  8. Lederballe Pedersen O., Christensen C. K., Mikkelsen E., Rämsch K. D. Relationship between the antihypertensive effect and steady-state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol. 1980 Oct;18(4):287–293. doi: 10.1007/BF00561384. [DOI] [PubMed] [Google Scholar]
  9. McAllister R. G., Jr, Kirsten E. B. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):418–426. doi: 10.1038/clpt.1982.54. [DOI] [PubMed] [Google Scholar]
  10. Mitchell L. B., Schroeder J. S., Mason J. W. Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review. Am J Cardiol. 1982 Feb 18;49(3):629–635. doi: 10.1016/s0002-9149(82)80022-2. [DOI] [PubMed] [Google Scholar]
  11. Nagao T., Sato M., Nakajima H., Kiyomoto A. Studies on a new 1, 5-benzothiazepine derivative (CRD-401). II. Vasodilator actions. Jpn J Pharmacol. 1972 Feb;22(1):1–10. doi: 10.1254/jjp.22.1. [DOI] [PubMed] [Google Scholar]
  12. Oyama Y., Imai Y., Nakaya H., Kanda K., Satoh T. The effects of diltiazem hydrochloride on the cardiac conduction: a clinical study of His bundle electrogram. Jpn Circ J. 1978 Nov;42(11):1257–1264. doi: 10.1253/jcj.42.1257. [DOI] [PubMed] [Google Scholar]
  13. Rosenthal S. J., Ginsburg R., Lamb I. H., Baim D. S., Schroeder J. S. Efficacy of diltiazem for control of symptoms of coronary arterial spasm. Am J Cardiol. 1980 Dec 1;46(6):1027–1032. doi: 10.1016/0002-9149(80)90362-8. [DOI] [PubMed] [Google Scholar]
  14. Rovel V., Mitchard M., Morselli P. L. Simple sensitive and specific gas chromatographic method for the quantification of diltiazem human body fluids. J Chromatogr. 1977 Aug 11;138(2):391–398. doi: 10.1016/s0021-9673(00)94974-4. [DOI] [PubMed] [Google Scholar]
  15. Sato M., Nagao T., Yamaguchi I., Nakajima H., Kiyomoto A. Pharmacological studies on a new l,5-benzothiazepine derivative (CRD-401). Arzneimittelforschung. 1971 Sep;21(9):1338–1343. [PubMed] [Google Scholar]
  16. Smith C. D., McKendry R. J. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet. 1982 Dec 11;2(8311):1299–1301. doi: 10.1016/s0140-6736(82)91508-2. [DOI] [PubMed] [Google Scholar]
  17. Vayssairat M., Capron L., Fiessinger J. N., Mathieu J. F., Housset E. Calcium channel blockers and Raynaud's disease. Ann Intern Med. 1981 Aug;95(2):243–243. doi: 10.7326/0003-4819-95-2-243_2. [DOI] [PubMed] [Google Scholar]
  18. WHITNEY R. J. The measurement of volume changes in human limbs. J Physiol. 1953 Jul;121(1):1–27. doi: 10.1113/jphysiol.1953.sp004926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wellens H. J., Tan S. L., Bär F. W., Düren D. R., Lie K. I., Dohmen H. M. Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia. Br Heart J. 1977 Oct;39(10):1058–1066. doi: 10.1136/hrt.39.10.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wright B. M., Dore C. F. A random-zero sphygmomanometer. Lancet. 1970 Feb 14;1(7642):337–338. doi: 10.1016/s0140-6736(70)90709-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES